Abstract
There is limited consensus on the optimal treatment strategy for cM1a non-small-cell lung cancer (NSCLC) in the setting of contralateral lung involvement. Current National Comprehensive Cancer Network (NCCN) guidelines recommend surgery for a subset of Stage IVA that is node-negative (N0 M1a) where primary tumors present with a solitary contralateral lung nodule; however, no clear recommendations have been made for node-positive disease. This study sought to assess long-term survival of patients receiving either systemic therapy (with or without radiation) or multimodality therapy that included surgery for cM1a NSCLC with contralateral lung involvement.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
